| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
There are various tumor signaling pathway. However, the role of estrogen signaling pathway are not well understood in lung adenocarcinoma.In this study, we report that aromatase and ERβ expression are independent, unfavorable prognostic factors in EGFR wild-type lung adenocarcinoma. We suggest that tumor progression caused by stimulation of estrogen signaling pathway could be enhanced by localized autocrine or paracrine production of estrogen by aromatase, especially in EGFR wild-type lung adenocarcinoma. Aromatase and ERβ can be surrogate markers for therapy selection and prognosis prediction in lung adenocarcinoma. Our findings revealed that EGFR wild-type lung adenocarcinoma patients with high aromatase expression are a suitable subset for aromatase inhibitor (AI) treatment.
|
